Acceleron Pharma

At Acceleron, we aim to transform the lives of people suffering from cancer and orphan diseases by discovering and developing innovative therapies.

Acceleron scientists have world-leading expertise in developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, bone, and blood vessels. Based on this expertise, we have built a robust pipeline of protein therapeutics targeted to key mechanisms underlying blood diseases and cancer.

Since our founding in 2004, Acceleron has brought four distinct, internally-discovered, developed and manufactured products into clinical trials, and has established collaborations with leading biopharmaceutical companies and research institutions to bring these products to the patients who need them.

Type
Public
HQ
Cambridge, US
Founded
2004
Employees
106 (est)
Acceleron Pharma was founded in 2004 and is headquartered in Cambridge, US

Key People at Acceleron Pharma

John Knopf

John Knopf

CEO, Founder
Richard F. Pops

Richard F. Pops

Board Member
Terrance G. McGuire

Terrance G. McGuire

Board of Directors
Ed Kania

Ed Kania

Board of Directors
Jean George

Jean George

Board of Directors
Tony Evnin

Tony Evnin

Board of Directors
George Golumbeski

George Golumbeski

Board of Directors
Joseph S. Zakrzewski

Joseph S. Zakrzewski

Board of Directors
Edwin Kania

Edwin Kania

Board of Directors
Anthony Evnin

Anthony Evnin

Board of Directors
Tom Maniatis

Tom Maniatis

Board of Directors
Wylie W. Vale

Wylie W. Vale

Board of Directors
Terry McGuire

Terry McGuire

Board of Directors
Matthew L. Sherman

Matthew L. Sherman

Chief Medical Officer
Nancy Sullivan

Nancy Sullivan

VP, Human Resources
Robert Steininger

Robert Steininger

SVP, Manufacturing
Steven Ertel

Steven Ertel

Chief Business Officer

Acceleron Pharma Locations

Cambridge, US

Acceleron Pharma Metrics

Acceleron Pharma Summary

Market capitalization

$964 M

Closing share price

$26.2
Acceleron Pharma's current market capitalization is $964 M.

Acceleron Pharma Financials

Acceleron Pharma's revenue is $18.1 M in FY, 2015 which is 23.68% increase from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

$57.2 M$14.6 M$18.1 M

Operating income

$6.95 M$-55.5 M$-60.9 M

Net Income

$-21.9 M$-51.3 M$-63.9 M

Operating cash flow

$73.6 M$63.3 M$-149 M

    Acceleron Pharma Market Value History

    Acceleron Pharma Online Presence

    Acceleron Pharma News

    Acceleron Pharma Company Life

    You may also be interested in